New Antibiotics of a Novel Class I


Infections caused by hard-to-treat methicillin-resistant Staphylococcus aureus (MRSA) are a serious global public-health concern, as MRSA has become broadly resistant to many classes of antibiotics. Researcher at the University of Notre Dame discovered a new class of non-β-lactam antibiotics, the oxadiazoles, which inhibit penicillin-binding protein 2a (PBP2a) of MRSA. The oxadiazoles show bactericidal activity against vancomycin and linezolid-resistant MRSA and other Gram-positive bacterial strains, in-vivo efficacy in a mouse model of infection, and have 100% oral bioavailability.


Patent Information:
For Information, Contact:
Richard Cox
Director, Technology Commercialization
University of Notre Dame
(574) 631-5158
Shahriar Mobashery
Dusan Hesek
Mayland Chang
© 2018. All Rights Reserved. Powered by Inteum